SK Biopharmaceuticals launches AI digital health business with Eurofarma in Ontario
SK Biopharmaceuticals, in partnership with Eurofarma, is launching Mentis Care, a new AI digital health joint venture, in Toronto, Ontario.
Source: Invest Ontario
SK Biopharmaceuticals launches AI digital health business with Eurofarma in Ontario
SK Biopharmaceuticals, in partnership with Eurofarma, is launching Mentis Care, a new AI digital health joint venture, in Toronto, Ontario.
New joint venture lands at MaRS, driving neurological care innovation with Ontario’s AI and life sciences talent TORONTO, Ontario, October 21, 2025 – SK Biopharmaceuticals, part of South Korean conglomerate SK Group, and Eurofarma, a Brazil-based multinational pharmaceutical company, are expanding their presence in North America with the launch of a new AI digital health joint venture, Mentis Care, in Toronto, Ontario. Focused on developing AI-driven epilepsy management solutions, Mentis Care will combine electroencephalogram (EEG) monitoring technology with predictive algorithms to help patients anticipate and manage seizures more effectively. The technology analyzes neurological patterns in real time, identifying precursors to seizure events and providing patients with advance warning. This 50:50 joint venture marks both SK Biopharmaceuticals’ and Eurofarma’s first digital health initiative in North America and their first Canadian business operation. It aims to address the unmet need for predictive and preventive tools that complement pharmaceutical treatment of epilepsy. SK Biopharmaceuticals is expanding beyond pharmaceuticals into digital healthcare to open new possibilities in patient care. Through Mentis Care, we will advance toward patient-centered innovation by integrating AI and clinical data to improve epilepsy treatment. Donghoon Lee CEO of SK Biopharmaceuticals For Eurofarma, the JV represents the future we envision for healthcare, combining digital technologies and medicines for a transformative and positive leap in patients’ lives. We are a reference in central nervous system treatments in Latin America, with a broad portfolio of medicines and close relationships with psychiatrists and neurologists. For some years now, we have added digital innovation investments to our R&D activities, and since 2022, we have maintained a small operation in North America. With this new partnership, we will strengthen these fronts in a single move. Rodrigo Pereira Director of Entrepreneurship and Digital at Eurofarma Located at the MaRS Discovery District, Mentis Care’s Toronto R&D centre joins a thriving, talent-dense ecosystem anchored by the Vector Institute and a network of world-class universities and research hospitals that are driving the convergence of AI and life sciences innovation. This investment builds on the long-standing partnership between Ontario and South Korean companies, which have made significant contributions across the province’s advanced manufacturing and clean technology sectors in recent years. The launch of Mentis Care represents a new milestone in this collaboration, extending joint innovation into the growing digital health space. Ontario’s life sciences sector is a pillar of our economy, driven by world-class talent, cutting-edge research, and a thriving ecosystem that attracts global investment. We congratulate SK Biopharmaceuticals and Eurofarma on this partnership, and look forward to seeing Mentis Care leverage Ontario's expertise and sector strengths to deliver AI-driven healthcare breakthroughs and strengthen our province’s leadership in innovative healthcare technologies. Hon. Vic Fedeli Minister of Economic Development, Job Creation and Trade Mentis Care plans to expand its local team and strengthen industry-academic collaborations, with the objective of transforming neurological care through AI to improve patient outcomes. Mentis Care is an AI-driven digital health company with a mission to help patients with epilepsy live safer and more independently through AI-powered seizure prediction and monitoring. By combining the innovation capabilities of our partners, SK Biopharmaceuticals and Eurofarma, we aim to establish a new standard in digital epilepsy management for patients worldwide. Hassan Kotob CEO of Mentis Care Invest Ontario supported the expansion by connecting the company with key partners and programs, ensuring Mentis Care’s North American debut is set up for success. We’re proud that SK Biopharmaceuticals and Eurofarma chose Ontario as the base for their next phase of growth. This expansion reflects the confidence international investors have in the Ontario life sciences community and aligns with our strategy to diversify and deepen partnerships that contribute to a more resilient economy. Khawar Nasim CEO of Invest Ontario The decision by SK Biopharmaceuticals and Eurofarma to choose Toronto over other global cities is a powerful vote of confidence in our region’s competitiveness. Mentis Care joins a growing roster of global companies investing in AI-powered life sciences here, each reinforcing Toronto’s position as one of the world’s most dynamic innovation centres. Stephen Lund CEO of Toronto Global Invest Ontario continues to partner with forward-looking companies to unlock new opportunities and accelerate their success, while creating meaningful jobs and strengthening the province’s economy for the future. For more information about Invest Ontario, please visit www.investontario.ca.
/taxonomy/term/6
/taxonomy/term/26